BR0207434A - Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos - Google Patents

Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos

Info

Publication number
BR0207434A
BR0207434A BR0207434-6A BR0207434A BR0207434A BR 0207434 A BR0207434 A BR 0207434A BR 0207434 A BR0207434 A BR 0207434A BR 0207434 A BR0207434 A BR 0207434A
Authority
BR
Brazil
Prior art keywords
accelerated
domiciliation
lymphocyte
medicament
agents
Prior art date
Application number
BR0207434-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Marc Bigaud
Volker Brinkmann
Tomasz Sablinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104438A external-priority patent/GB0104438D0/en
Priority claimed from GB0105000A external-priority patent/GB0105000D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0207434A publication Critical patent/BR0207434A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/131Amines acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR0207434-6A 2001-02-22 2002-02-21 Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos BR0207434A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0104438A GB0104438D0 (en) 2001-02-22 2001-02-22 Organic compounds
GB0105000A GB0105000D0 (en) 2001-02-28 2001-02-28 Organic compounds
PCT/EP2002/001860 WO2002067915A1 (en) 2001-02-22 2002-02-21 Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function

Publications (1)

Publication Number Publication Date
BR0207434A true BR0207434A (pt) 2004-07-06

Family

ID=26245749

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207434-6A BR0207434A (pt) 2001-02-22 2002-02-21 Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos

Country Status (11)

Country Link
US (2) US20040087662A1 (https=)
EP (1) EP1368015B1 (https=)
JP (1) JP4318921B2 (https=)
CN (1) CN100479814C (https=)
AT (1) ATE335475T1 (https=)
BR (1) BR0207434A (https=)
CA (1) CA2435739A1 (https=)
DE (1) DE60213766T2 (https=)
ES (1) ES2267993T3 (https=)
PT (1) PT1368015E (https=)
WO (1) WO2002067915A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0209319A (pt) * 2001-06-08 2004-07-20 Novartis Ag Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina
DK1471054T3 (da) 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP1806338B1 (en) * 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
PL1932522T3 (pl) * 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2659598A1 (en) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928572A (en) * 1971-02-11 1975-12-23 Ayerst Mckenna & Harrison Myriocin and process of preparation
DE69321823T2 (de) * 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
WO1997024112A1 (en) * 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
ES2240868T3 (es) * 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
BR0209319A (pt) * 2001-06-08 2004-07-20 Novartis Ag Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina

Also Published As

Publication number Publication date
JP4318921B2 (ja) 2009-08-26
PT1368015E (pt) 2006-12-29
US20080015261A1 (en) 2008-01-17
US20040087662A1 (en) 2004-05-06
CN1492757A (zh) 2004-04-28
DE60213766T2 (de) 2007-08-02
EP1368015B1 (en) 2006-08-09
ATE335475T1 (de) 2006-09-15
DE60213766D1 (de) 2006-09-21
JP2004527490A (ja) 2004-09-09
CN100479814C (zh) 2009-04-22
HK1060855A1 (en) 2004-08-27
WO2002067915A1 (en) 2002-09-06
ES2267993T3 (es) 2007-03-16
EP1368015A1 (en) 2003-12-10
CA2435739A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
BR0309492A (pt) Uso de pelo menos um álcool ramificado alcoxilado
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
AU2016204344A1 (en) Improved methods and compositions for wound healing
BRPI0412404A (pt) uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea
ATE340844T1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
CO5221115A1 (es) Nuevos compuestos fungicidas
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
BR0114390A (pt) éteres de 7-desmetilrapamicina
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
ATE281431T1 (de) Resorcin-derivate
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
BR0207434A (pt) Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos
CO5221025A1 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos
TR199901104T2 (xx) Farmas�tik bile�ikler.
MY122877A (en) Composition.
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
AR036581A1 (es) Composicion herbicida
WO2006034001A3 (en) Methods of treating hiv infection
ECSP066481A (es) Formulaciones que contienen cobre
WO2004091436A3 (en) Methods and compositions for treating ocular disease
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
DE602004013011D1 (de) Haarbehandlungszusammensetzungen
BR0009194A (pt) Composição do resorcinol
ATE418613T1 (de) Antimikrobielle zusammensetzungen
AU5276802A (en) Embalming fluid

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.